MBX Biosciences, Inc.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's mission is to improve the standard of care for these conditions, enabling patients to live fuller and healthier lives. Headquartered in Carmel, Indiana, United States, MBX Biosciences was founded in 2018 and incorporated as a Delaware corporation in April 2019.

The company leverages its proprietary Precision Endocrine Peptide (PEP™) platform to develop a pipeline of therapeutic candidates. Key product candidates include Canvuparatide (MBX 2109), currently in Phase 3 clinical trials for chronic hypoparathyroidism; Imapextide (MBX 1416), in Phase 2 development for post-bariatric hypoglycemia; and MBX 4291, a GLP-1/GIP co-agonist prodrug in Phase 1 clinical evaluation for obesity. MBX Biosciences also has additional early-stage obesity candidates, such as MBX 5XXX and MBX 6XXX, in its discovery pipeline.

Led by President and CEO Kent Hawryluk, MBX Biosciences became a publicly traded company on Nasdaq under the ticker symbol MBX on September 13, 2024. The company has secured significant investor backing, including a $63.5 million Series C financing round in August 2024, contributing to over $213 million in total funding to advance its pipeline and operations into 2026.